The company's comparison of its ADCs to Enhertu seems farfetched.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.

The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.